Safety of Short-Term Trimethoprim-Sulfamethoxazole Use for Uncomplicated Cystitis: A Nationwide Retrospective Cohort Study.

Key Points

• To evaluate the safety of short-term trimethoprim-sulfamethoxazole (TMP-SMX) use for uncomplicated cystitis compared to fluoroquinolones.
• Conducted a nationwide retrospective cohort study in Japan
• Compared adverse events and treatment failure rates between TMP-SMX and fluoroquinolones
• Analyzed data from patients diagnosed with uncomplicated cystitis
• No increased risk of adverse events observed with TMP-SMX compared to fluoroquinolones
• Treatment failure rates were similar for both TMP-SMX and fluoroquinolones
• TMP-SMX is suggested as a reasonable first-line option for acute uncomplicated cystitis